GCIA
NDRM

Gabelli & Co Investment Advisers’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-364,548
Closed -$14.2M – 212
2017
Q3 		$14.2M Buy
+364,548
New +$13.4M 1.64% 17

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

Gabelli & Co Investment Advisers's NDRM Position: Q4 2017 in Review

Gabelli & Co Investment Advisers sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 364,548 shares — an estimated $14.2M sold.

Gabelli & Co Investment Advisers first reported a position in NDRM in Q3 2017 and held it in 1 quarter. The position peaked at $14.2M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Gabelli & Co Investment Advisers reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 364,548 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $14.2M.
  • Gabelli & Co Investment Advisers first reported a position in NeuroDerm Ltd. Ordinary Shares in Q3 2017 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's NeuroDerm Ltd. Ordinary Shares position peaked at $14.2M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Gabelli & Co Investment Advisers's 13F filing for Q4 2017, filed 2 Feb 2018.